Title:
TUMOR-TARGETED FUSION PROTEIN TYPE MEDICAMENT PRECURSOR TAKING INTERLEUKIN 2 AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2024/051817
Kind Code:
A1
Abstract:
The present invention relates to a tumor-targeted fusion protein type medicament precursor taking interleukin 2 as an active ingredient.
Inventors:
FU YANGXIN (CN)
GAO YU (CN)
REN ZHENHUA (CN)
GAO YU (CN)
REN ZHENHUA (CN)
Application Number:
PCT/CN2023/117716
Publication Date:
March 14, 2024
Filing Date:
September 08, 2023
Export Citation:
Assignee:
BEIJING CHANGPING LABORATORY (CN)
International Classes:
C07K19/00; A61K47/65; A61K47/66; A61K47/68; A61P35/00; C07K14/55
Domestic Patent References:
| WO2021097376A1 | 2021-05-20 |
Foreign References:
| CN113840832A | 2021-12-24 | |||
| CN113874390A | 2021-12-31 | |||
| CN1665543A | 2005-09-07 | |||
| US20050033026A1 | 2005-02-10 | |||
| CN102286074A | 2011-12-21 |
Other References:
HSU ERIC J., CAO XUEZHI, MOON BENJAMIN, BAE JOONBEOM, SUN ZHICHEN, LIU ZHIDA, FU YANG-XIN: "A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy", NATURE COMMUNICATIONS, vol. 12, no. 1, 1 December 2021 (2021-12-01), XP055924897, DOI: 10.1038/s41467-021-22980-w
Attorney, Agent or Firm:
CHINA SCIENCE PATENT & TRADEMARK AGENT LTD. (CN)
Download PDF: